Abrahamsen B. Adverse Effects of Bisphosphonates. Calcif Tissue Int. 2010; 86: 421-435.
Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituxumab: modes of action, remaining dispute and future perspective. Future Oncology. 10(15): 2481-2492.
Adami S, Zamberlan N. Adverse Effects of Bisphosphonates: A Comparative Review. Drug Safety. 1996; 14(3): 156-170.
Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13 Suppl 2:S3-S10.
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug.Seminars in Arthritis and Rheumatism. 1993;23:82-91.
Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. The Journal of Immunology. 1996; 156(5): 1937-1941.
Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism. 2015;45:341-350.
Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008; 10(3): 218-227.
Pacher P, Nivorozhkin A, Szabo C. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol. Pharmacological reviews. 2006; 58(1): 87-114.
Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996 Jun; 97(12): 26922696.
Wallace S. Mechanism of action of colchicine. Arthritis & Rheumatism. 1965; 8(4): 744748.
Weiner LM, Surana R, Wang S. Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy. Nature Reviews Immunology. 2010 May; 10: 317-327.